Skip to main content

Table 3 Analyses of secondary outcomes in urologic cancers

From: Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis

Secondary outcomes No. of studies No. of cases Pooled HR (95% CI) P-value Heterogeneity
I2 Model
PFS 7 1554 1.92 (1.29, 2.88) 0.001 93 Random
CSS 2 600 2.58 (1.36, 4.91) 0.004 7 Random
ORR 2 448 0.40 (0.22, 0.71) 0.002 0 Fixed
DCR 2 448 0.93 (0.11, 8.05) 0.950 95 Random
  1. CI: confidence interval; CSS: cancer‐specific survival; DSS: disease‐specific survival; ORR: overall response rate; DCR: disease control rate; HR: hazard ratio; SII: systemic immune‐inflammation index